Novartis Ag (NVS) Net Cash Flow (2009 - 2025)
Novartis Ag recorded quarterly Net Cash Flow of -$2.1 billion in Q4 2025, down 144.65% quarter-over-quarter from -$860.0 million in Q3 2025, and up 60.53% year-over-year from -$1.3 billion in Q4 2024.
Novartis Ag's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$2.1 billion for Q4 2025.
- In Q4 2025, Net Cash Flow rose 60.53% year-over-year to -$2.1 billion; the TTM figure through Mar 2026 stood at -$3.8 billion (up 50.7% YoY), while the FY2025 annual figure was -$600.0 million, up 63.33% from the prior year.
- Net Cash Flow came in at -$2.1 billion for Q4 2025 at Novartis Ag, down from -$860.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $9.9 billion in Q3 2021 to a low of -$10.2 billion in Q2 2022.
- A 5-year average of -$757.0 million and a median of -$846.0 million in 2023 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow jumped 420.63% in 2021 and tumbled 18460.0% in 2022, its largest moves.
- Novartis Ag's Net Cash Flow stood at $35.0 million in 2021, then sank by 18460.0% to -$6.4 billion in 2022, then soared by 192.22% to $5.9 billion in 2023, then plunged by 189.94% to -$5.3 billion in 2024, then surged by 60.53% to -$2.1 billion in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$2.1 billion, -$860.0 million, and -$792.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.10 Bn |
| Dec 31, 2025 | -2.10 Bn |
| Sep 30, 2025 | -860.00 Mn |
| Sep 30, 2025 | -860.00 Mn |
| Jun 30, 2025 | -792.00 Mn |
| Jun 30, 2025 | -792.00 Mn |
| Dec 31, 2024 | -5.33 Bn |
| Dec 31, 2024 | -5.33 Bn |
| Sep 30, 2024 | -756.00 Mn |
| Sep 30, 2024 | -756.00 Mn |
| Jun 30, 2024 | -1.53 Bn |
| Jun 30, 2024 | -1.53 Bn |
| Mar 31, 2024 | -899.00 Mn |
| Mar 31, 2024 | -899.00 Mn |
| Dec 31, 2023 | 5.93 Bn |
| Dec 31, 2023 | 5.93 Bn |
| Sep 30, 2023 | -832.00 Mn |
| Sep 30, 2023 | -832.00 Mn |
| Jun 30, 2023 | -1.11 Bn |
| Jun 30, 2023 | -1.11 Bn |
| Dec 31, 2022 | -6.43 Bn |
| Dec 31, 2022 | -6.43 Bn |
| Jun 30, 2022 | -10.18 Bn |
| Jun 30, 2022 | -10.18 Bn |
| Dec 31, 2021 | 35.00 Mn |
| Dec 31, 2021 | 35.00 Mn |
| Sep 30, 2021 | 9.89 Bn |
| Sep 30, 2021 | 9.89 Bn |
| Jun 30, 2021 | 1.29 Bn |
| Jun 30, 2021 | 1.29 Bn |
| Mar 31, 2021 | 1.57 Bn |
| Mar 31, 2021 | 1.57 Bn |
| Dec 31, 2020 | 4.75 Bn |
| Dec 31, 2020 | 4.75 Bn |
| Sep 30, 2020 | 1.90 Bn |
| Sep 30, 2020 | 1.90 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Dec 31, 2019 | 318.00 Mn |
| Dec 31, 2019 | 318.00 Mn |
| Jun 30, 2019 | 2.61 Bn |
| Jun 30, 2019 | 2.61 Bn |
| Dec 31, 2018 | -3.48 Bn |
| Dec 31, 2018 | -3.48 Bn |
| Sep 30, 2018 | -886.00 Mn |
| Sep 30, 2018 | -886.00 Mn |
| Jun 30, 2018 | 6.74 Bn |
| Jun 30, 2018 | 6.74 Bn |
| Dec 31, 2017 | -996.00 Mn |
| Dec 31, 2017 | -996.00 Mn |
| Sep 30, 2017 | -685.00 Mn |
| Sep 30, 2017 | -685.00 Mn |
| Jun 30, 2017 | 233.00 Mn |
| Jun 30, 2017 | 233.00 Mn |
| Mar 31, 2017 | -388.00 Mn |
| Mar 31, 2017 | -388.00 Mn |
| Dec 31, 2016 | -847.00 Mn |
| Dec 31, 2016 | -847.00 Mn |
| Sep 30, 2016 | -1.03 Bn |
| Sep 30, 2016 | -1.03 Bn |
| Jun 30, 2016 | -593.00 Mn |
| Jun 30, 2016 | -593.00 Mn |
| Mar 31, 2016 | -564.00 Mn |
| Mar 31, 2016 | -564.00 Mn |
| Sep 30, 2015 | -613.00 Mn |
| Sep 30, 2015 | -613.00 Mn |
| Dec 31, 2014 | -1,529.00 |
| Dec 31, 2014 | -1,529.00 |
| Sep 30, 2014 | 54.00 |
| Sep 30, 2014 | 54.00 |
| Jun 30, 2014 | -777.00 |
| Jun 30, 2014 | -777.00 |
| Dec 31, 2013 | 153.00 |
| Dec 31, 2013 | 153.00 |
| Sep 30, 2013 | -753.00 |
| Sep 30, 2013 | -753.00 |
| Jun 30, 2013 | -600.00 |
| Jun 30, 2013 | -600.00 |
| Mar 31, 2013 | 696.00 |
| Mar 31, 2013 | 696.00 |
| Jun 30, 2012 | -723.00 |
| Jun 30, 2012 | -723.00 |
| Mar 31, 2012 | -445.00 |
| Mar 31, 2012 | -445.00 |
| Dec 31, 2011 | -824.00 |
| Dec 31, 2011 | -824.00 |
| Sep 30, 2011 | -569.00 |
| Sep 30, 2011 | -569.00 |
| Jun 30, 2011 | 110.00 |
| Jun 30, 2011 | 110.00 |
| Mar 31, 2011 | 4.00 |
| Mar 31, 2011 | 4.00 |
| Dec 31, 2010 | 385.00 |
| Dec 31, 2010 | 385.00 |
| Jun 30, 2010 | 950.00 |
| Jun 30, 2010 | 950.00 |
| Mar 31, 2010 | 2,193.00 |
| Mar 31, 2010 | 2,193.00 |
| Dec 31, 2009 | 12.19 Bn |
| Dec 31, 2009 | 12.19 Bn |
| Sep 30, 2009 | 3,597.00 |
| Sep 30, 2009 | 3,597.00 |
| Jun 30, 2009 | -114.00 |
| Jun 30, 2009 | -114.00 |
| Mar 31, 2009 | -437.00 |
| Mar 31, 2009 | -437.00 |